While the U.S. Supreme Court rejected Amgen's functionally defined anti-PCSK9 antibody claims based on its high bar for enablement, the ...
A privately held biopharmaceutical company based in the United States. Its development and planned commercialization ...
AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new data – ...
AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in LDL-cholesterol when added to standard therapy, as it tries to narrow a lead ...
The American College of Cardiology publishes new recommendations for peripheral artery disease diagnosis and treatment among adults with diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback